(Australia-NewsWire.Com, August 24, 2017 ) Antibodies (Abs) are a large, Y-shaped protein produced by differentiated B-Cells (Known as Plasma cells) that are used by the immune system to detect and neutralize pathogens such as Viruses and bacteria. Antibodies can be triggered by and directed at microorganisms, foreign proteins, or toxins.
Major factors that are influencing the Asia-Pacific Antibodies Industry are rising rate of adoption to therapeutic antibodies in cost sensitive Industry, innovative products, growing chronic illnesses due to population shift and increasing longevity, quick approval for breakthrough therapies by regulatory authorities, and adoption of diagnostic antibodies. Increasing cost of treatment and side effects associated with antibodies treatment are the restraints that are affecting the growth of the Industry.
Based on product type, the Industry is segmented into Monoclonal Antibodies, Polyclonal Antibodies, and Anti-body drug complexes. The monoclonal antibodies are further segmented into Murine, Chimeric, Humanized, and Human. The polyclonal antibodies are further categorized into Type I, Type II, Type III, Type IV, Type V, Type VI, Type VII, Type VIII. The Antibody-Drug Complexes are further segmented into Immunogen Technology, Seattle Genetics Technology, and Immunomedics Technology.
Based on Indication, the Industry is segmented into Cancer, Auto immune diseases, Infectious diseases, cardiovascular diseases, and CNS disorders, others (Inflammatory, Microbial Diseases, & Other). Based on end users, the Industry is segmented into Hospitals/Clinics, Research institute, Diagnostics laboratories.
Based on Application, the Industry is segmented into Medical, Experimental. The Experimental segment is further categorized into Western blot, ELISA, Radioimmune Assays, immunofluorescence, others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry). Based on Geography, the Asia-Pacific Antibodies Industry is analysed under various regions namely China, India, Japan and Australia.
Major players dominating the Asia-Pacific Antibodies Industry are Shimadzu corporation, Novartis AG, Pfizer Inc., ThermoFisher Scientific Inc., Eli Lilly and company, Takara Bio, Levena Bio pharma, F. Hoffmann-La Roche Ltd., Bio-Rad laboratories, Inc.
Key Points from Table of Contents Overview Executive Summary Key Inferences New Developments Drivers, Restraints, Opportunities, and Challenges Analysis (DROC) Asia Pacific Antibodies Industry: Segmentation By Product Type o Monoclonal Antibodies o Polyclonal Antibodies o Antibody-Drug Complexes By Indication o Cancer o Autoimmune Diseases o Infectious Diseases o Cardiovascular Diseases o CNS Disorders o Others (Inflammatory, Microbial Diseases, & Other) End User o Hospitals/Clinics o Research Institute o Diagnostic Laboratories Application o Medical o Experimental Geographical Analysis China India Japan South Korea Australia Strategic Analysis PESTLE analysis Porters Five analysis Industry Leaders' Analysis Competitive Landscape
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.